JP2017536111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536111A5 JP2017536111A5 JP2017522640A JP2017522640A JP2017536111A5 JP 2017536111 A5 JP2017536111 A5 JP 2017536111A5 JP 2017522640 A JP2017522640 A JP 2017522640A JP 2017522640 A JP2017522640 A JP 2017522640A JP 2017536111 A5 JP2017536111 A5 JP 2017536111A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- tim
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 134
- 102000036639 antigens Human genes 0.000 claims description 134
- 108091007433 antigens Proteins 0.000 claims description 134
- 239000012634 fragment Substances 0.000 claims description 129
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 48
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 47
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 45
- 238000000338 in vitro Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000003915 cell function Effects 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 230000017274 T cell anergy Effects 0.000 claims description 7
- 231100000433 cytotoxic Toxicity 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1419089.6 | 2014-10-27 | ||
| GB1419092.0 | 2014-10-27 | ||
| GB201419092A GB201419092D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3 antibodies |
| GB201419089A GB201419089D0 (en) | 2014-10-27 | 2014-10-27 | Anti-TIM-3 antibodies |
| PCT/SG2015/050415 WO2016068803A1 (en) | 2014-10-27 | 2015-10-27 | Anti-tim-3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536111A JP2017536111A (ja) | 2017-12-07 |
| JP2017536111A5 true JP2017536111A5 (enExample) | 2018-12-13 |
| JP6709215B2 JP6709215B2 (ja) | 2020-06-10 |
Family
ID=55857945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522640A Active JP6709215B2 (ja) | 2014-10-27 | 2015-10-27 | 抗ｔｉｍ−３抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10259874B2 (enExample) |
| EP (1) | EP3212231B1 (enExample) |
| JP (1) | JP6709215B2 (enExample) |
| KR (1) | KR20170075778A (enExample) |
| CN (2) | CN110294807B (enExample) |
| AU (1) | AU2015340056A1 (enExample) |
| CA (1) | CA2965960A1 (enExample) |
| SG (2) | SG11201703403TA (enExample) |
| WO (1) | WO2016068803A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703403TA (en) * | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| TW201639888A (zh) | 2015-03-06 | 2016-11-16 | 索倫多醫療公司 | 結合ｔｉｍ３之抗體治療劑 |
| EP3337826A1 (en) * | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| KR102366813B1 (ko) | 2016-05-27 | 2022-02-24 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| PE20190418A1 (es) * | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| TWI769174B (zh) | 2016-08-26 | 2022-07-01 | 英屬開曼群島商百濟神州有限公司 | 抗tim-3抗體及其用途 |
| JP7265984B2 (ja) * | 2016-10-21 | 2023-04-27 | アディマブ， エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
| US11312761B2 (en) | 2016-10-21 | 2022-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| CN108264557B (zh) * | 2016-12-30 | 2021-08-24 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用 |
| EP3565598A4 (en) * | 2017-01-03 | 2020-10-28 | Trellis Bioscience, LLC | NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS |
| CN110234662A (zh) | 2017-01-26 | 2019-09-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| EP3658185A4 (en) | 2017-07-28 | 2021-07-14 | Phanes Therapeutics, Inc. | ANTI-TIM-3 ANTIBODIES AND USES THEREOF |
| IL310079A (en) | 2017-08-28 | 2024-03-01 | Bristol Myers Squibb Co | TIM-3 antagonists for the treatment and diagnosis of cancer |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| KR102813913B1 (ko) * | 2018-01-12 | 2025-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| US11795221B2 (en) | 2018-02-28 | 2023-10-24 | WuXi Biologics Ireland Limited | Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof |
| CN110272489B (zh) * | 2018-03-15 | 2023-08-22 | 上海健信生物医药科技有限公司 | 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途 |
| CN110305216B (zh) * | 2018-03-20 | 2022-09-02 | 无锡智康弘义生物科技有限公司 | 新型抗tim-3抗体 |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| CN111989341B (zh) * | 2018-04-12 | 2023-06-02 | 南京维立志博生物科技有限公司 | 结合tim-3的抗体及其用途 |
| JP7328324B2 (ja) * | 2018-04-24 | 2023-08-16 | アンプソース・バイオファーマ・シャンハイ・インコーポレイテッド | Ｔｉｍ－３に対する抗体およびその使用 |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| JP7634993B2 (ja) * | 2018-06-19 | 2025-02-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| EP3873611A1 (en) * | 2018-11-01 | 2021-09-08 | Merck Patent GmbH | Anti-tim-3 antibodies |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| JP7440509B2 (ja) * | 2018-11-09 | 2024-02-28 | ベス イスラエル デアコネス メディカル センター | Ｃｄｃｐ１－標的化療法 |
| TW202039557A (zh) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| CN110498855A (zh) * | 2019-07-25 | 2019-11-26 | 钟小泉 | 一种tim-3抗体及其用途 |
| CN110922478B (zh) * | 2019-12-07 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN113150150B (zh) * | 2020-02-24 | 2023-08-11 | 苏州恒康生命科学有限公司 | Tim3结合分子及其应用 |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| CN112094348B (zh) * | 2020-09-22 | 2021-11-30 | 首都医科大学附属北京胸科医院 | 抗人Tim3抗体或其功能性片段及其应用 |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| KR20230137948A (ko) * | 2021-01-22 | 2023-10-05 | 엘피스 바이오파마슈티컬즈 | Cd19 및 cd22에 결합하는 이중특이적 키메라 항원 수용체 |
| EP4083065A1 (en) | 2021-01-28 | 2022-11-02 | NantBio, Inc. | Anti-tim3 monoclonal antibodies and chimeric antigen receptors |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CN114181311B (zh) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用 |
| WO2023168195A2 (en) * | 2022-03-04 | 2023-09-07 | The Scripps Research Institute | Human broadly neutralizing antibodies against betacoronaviruses |
| US20250206775A1 (en) | 2022-03-18 | 2025-06-26 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| EP4658687A1 (en) | 2023-01-31 | 2025-12-10 | University of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69638269D1 (de) | 1995-06-14 | 2010-11-18 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| ES2192426B1 (es) | 2000-05-11 | 2005-02-16 | Universidad De Vigo | Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia. |
| US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| US8067544B2 (en) | 2003-03-19 | 2011-11-29 | Curagen Corporation | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
| CN1902227A (zh) | 2003-10-03 | 2007-01-24 | 布赖汉姆妇女医院 | Tim－3配体及其方法 |
| WO2006138729A2 (en) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Receptor antagonists for treatment of metastatic bone cancer |
| EP2548583A3 (en) | 2005-11-10 | 2013-02-27 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| US20110059106A1 (en) * | 2008-01-29 | 2011-03-10 | Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| ES2571235T3 (es) | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
| EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
| WO2011155607A1 (ja) * | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| CN102392038B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 一种删除转基因水稻精米中的外源基因的表达载体及其应用 |
| CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
| EP2879709B1 (en) | 2012-07-31 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Modulation of the immune response |
| CN109513003A (zh) * | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| CN103665164A (zh) * | 2012-10-24 | 2014-03-26 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测Tim-3的ELISA试剂盒 |
| US20150284459A1 (en) | 2012-10-31 | 2015-10-08 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| JP2014162739A (ja) * | 2013-02-22 | 2014-09-08 | National Institute Of Biomedical Innovation | 二重特異性抗体及び医薬組成物 |
| WO2015103072A1 (en) * | 2013-12-30 | 2015-07-09 | Epimab Biotherapeutics | Fabs-in-tandem immunoglobulin and uses thereof |
| CN103936853B (zh) * | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| SG11201703403TA (en) | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| CN104592388B (zh) | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
-
2015
- 2015-10-27 SG SG11201703403TA patent/SG11201703403TA/en unknown
- 2015-10-27 CA CA2965960A patent/CA2965960A1/en not_active Abandoned
- 2015-10-27 SG SG10201803042PA patent/SG10201803042PA/en unknown
- 2015-10-27 JP JP2017522640A patent/JP6709215B2/ja active Active
- 2015-10-27 WO PCT/SG2015/050415 patent/WO2016068803A1/en not_active Ceased
- 2015-10-27 CN CN201910641759.0A patent/CN110294807B/zh active Active
- 2015-10-27 CN CN201580071169.9A patent/CN107405397B/zh active Active
- 2015-10-27 US US15/521,685 patent/US10259874B2/en active Active
- 2015-10-27 EP EP15855010.3A patent/EP3212231B1/en active Active
- 2015-10-27 AU AU2015340056A patent/AU2015340056A1/en not_active Abandoned
- 2015-10-27 KR KR1020177014444A patent/KR20170075778A/ko not_active Withdrawn
-
2019
- 2019-03-06 US US16/294,474 patent/US11142574B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536111A5 (enExample) | ||
| JP2017538441A5 (enExample) | ||
| JP2018500924A5 (enExample) | ||
| JP2019519208A5 (enExample) | ||
| AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
| ES2751996T3 (es) | Moléculas de unión para BCMA y CD3 | |
| JP2018527912A5 (enExample) | ||
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2016529229A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| RU2017116847A (ru) | Антитела к pd-1 | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| JP2019535763A5 (enExample) | ||
| JP2018508215A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| JP2017029157A5 (enExample) | ||
| JP2019509737A5 (enExample) | ||
| WO2016168773A2 (en) | Optimized pne-based chimeric receptor t cell switches and uses thereof | |
| JP2017522903A5 (enExample) | ||
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| JP2018530331A5 (enExample) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela |